|Articles|September 1, 2002

Pharmaceutical Executive

  • Pharmaceutical Executive-09-01-2002

Dutch Government Just Says No

Author(s)Sarah Houlton

Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance.

Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance. It believes it should not have to pay for medi-cines for conditions brought on by unhealthy lifestyles, such as smoking and poor diet.

But plans to include cholesterol-reducing products on the list have worried the College voor Zorgverzekeringen (the Healthcare Insurance Board) which advises the government. The board has issued a report on statins, saying that their use should remain a part of basic health insurance because of their long-term preventive benefits.

Articles in this issue

about 24 years ago

More Statins = Fewer Heart Attacks

about 24 years ago

When Worlds Collide

about 24 years ago

Top European Trial Sponsors

about 24 years ago

Novo Nordisk Cancels Clinical Trials

about 24 years ago

Lilly Marketers Cross the Line

about 24 years ago

Spending Hits a Wall

about 24 years ago

Strangers in the Shadows

about 24 years ago

Plants and Patents

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.